StockData
Exagen Inc. logo

Exagen Inc. (XGN) stock

XGNNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3010% above fair value
$3.90+0.14 (+3.72%)

Close on Nov 18, 2026Market cap $94.48MP/E –Yield –

Exagen revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Exagen's revenue for the twelve months ending Jun 30, 2026 was $71.12M, up 20.8% year over year. For fiscal 2025 it was $66.58M, up 19.7% from the year before. The highest annual figure on record is $66.58M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$66.58M+19.7%
FY2024Dec 31, 2024$55.64M+5.9%
FY2023Dec 31, 2023$52.55M+15.3%
FY2022Dec 31, 2022$45.56M-5.7%
FY2021Dec 31, 2021$48.30M+15.1%
FY2020Dec 31, 2020$41.98M+3.9%
FY2019Dec 31, 2019$40.39M+24.5%
FY2018Dec 31, 2018$32.44M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$19.94M+15.9%
Q1 FY2026Mar 31, 2026$17.31M+11.7%
Q4 FY2025Dec 31, 2025$16.63M+21.8%
Q3 FY2025Sep 30, 2025$17.24M+37.9%
Q2 FY2025Jun 30, 2025$17.20M+14.2%
Q1 FY2025Mar 31, 2025$15.50M+7.5%
Q4 FY2024Dec 31, 2024$13.66M-0.8%
Q3 FY2024Sep 30, 2024$12.51M-6.8%
Q2 FY2024Jun 30, 2024$15.06M+6.6%
Q1 FY2024Mar 31, 2024$14.42M+28.4%
Q4 FY2023Dec 31, 2023$13.77M+7.2%
Q3 FY2023Sep 30, 2023$13.42M-8.9%
Q2 FY2023Jun 30, 2023$14.14M+85.9%
Q1 FY2023Mar 31, 2023$11.23M+8.0%
Q4 FY2022Dec 31, 2022$12.84M+1.2%
Q3 FY2022Sep 30, 2022$14.73M+20.2%
Q2 FY2022Jun 30, 2022$7.61M-40.4%
Q1 FY2022Mar 31, 2022$10.39M-1.8%
Q4 FY2021Dec 31, 2021$12.69M+0.2%
Q3 FY2021Sep 30, 2021$12.25M+13.7%
Q2 FY2021Jun 30, 2021$12.77M+42.7%
Q1 FY2021Mar 31, 2021$10.59M+10.5%
Q4 FY2020Dec 31, 2020$12.67M+24.0%
Q3 FY2020Sep 30, 2020$10.78M+3.2%
Q2 FY2020Jun 30, 2020$8.95M-14.6%
Q1 FY2020Mar 31, 2020$9.58M+3.5%
Q4 FY2019Dec 31, 2019$10.21M+5.9%
Q3 FY2019Sep 30, 2019$10.44M+26.9%
Q2 FY2019Jun 30, 2019$10.47M–
Q1 FY2019Mar 31, 2019$9.26M–
Q4 FY2018Dec 31, 2018$9.64M–
Q3 FY2018Sep 30, 2018$8.22M–

More Exagen figures

See a number that looks wrong?